- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07942077
FLASH Biomarker Study
Biomarker Characterization in Patients Undergoing Ultra-High Dose Rate (ConformalFLASH®) on the C-FLASH-01 Trial
This is a single-center, non-interventional biospecimen collection protocol that accompanies C-FLASH-01 (Protocol IBA-04-UP, IDE G260113), a pilot trial of ultra-high dose rate proton reirradiation (ConformalFLASH) for head and neck cancer. Blood and saliva will be collected from up to 10 participants enrolled on the C-FLASH-01 trial at three time points: 1) within 4 weeks before the start of radiotherapy, 2) within 3 days of the last day of radiotherapy, and 3) within 4 months after completion of radiotherapy.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
The study team hypothesize that biomarkers measurable in blood and saliva, including but not limited to cell-free DNA and cytokines, change over the course of ConformalFLASH reirradiation and are associated with normal tissue response/toxicity. This protocol does not include a study intervention; all radiotherapy is delivered under the separately approved parent protocol (Protocol IBA-04-UP, IDE G260113).
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Ching Lai
- Telefonnummer: 267-250-9244
- E-post: Ching.Lai@pennmedicine.upenn.edu
Studer Kontakt Backup
- Navn: Karen Tang
- Telefonnummer: 267-299-9618
- E-post: Karen.Tang1@Pennmedicine.upenn.edu
Studiesteder
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- Perelman Center for Advanced Medicine, Department of Radiation Oncology
-
Ta kontakt med:
- Ching Lai
- Telefonnummer: 267-250-9244
- E-post: Ching.Lai@pennmedicine.upenn.edu
-
Ta kontakt med:
- Karen Tang
- Telefonnummer: 267-299-9618
- E-post: Karen.Tang1@Pennmedicine.upenn.edu
-
Hovedetterforsker:
- Shervin Tabrizi, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Participants are recruited exclusively from among individuals enrolled on C-FLASH-01 (Protocol IBA-04-UP, IDE G260113) in the Department of Radiation Oncology at the University of Pennsylvania. No advertising, flyers, social media, or other external recruitment will be used, and no additional screening of the general population is required.
Beskrivelse
Inclusion Criteria:
- Enrolled on C-FLASH-01 (Protocol IBA-04-UP, IDE G260113) and planned to receive ConformalFLASH reirradiation
- Male or female, aged 18 years or older
- Provision of signed and dated informed consent for this biospecimen protocol
- Stated willingness to comply with the specimen collection
Exclusion Criteria:
- Any condition that, in the judgment of the investigator, makes repeated peripheral venipuncture unsafe or infeasible
- Inability to provide informed consent
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: OTHER
- Tidsperspektiver: PROSPECTIVE
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Batched analysis of Biomarker dynamics in blood Including but not limited to cell-free DNA and cytokines, following ConformalFLASH reirradiation for up to 10 participants.
Tidsramme: - Collect blood (16 mL) between baseline (Screening, Enrollment, and Baseline) - (Visit 1) - Collect Blood (16 mL) end of Radiotherapy (Visit 2) - Collect Blood (16 mL) within 4 months after completion of radiotherapy (Post-Radiotherapy) - (Visit 3)
|
Change in biomarker measures (e.g., cell-free DNA and cytokines) in plasma between baseline, end of radiotherapy, and within 4 months after completion of radiotherapy. At each time point, 16 mL of peripheral blood will be drawn by a trained phlebotomist or delegated study team member into Streck Cell-Free DNA BCT tubes and EDTA tubes. The maximum cumulative volume drawn under this protocol is 48 mL per participant. Streck tubes stabilize cell-free DNA for the cell-free DNA analyses; EDTA tubes provide plasma and buffy coat for cytokine analyses and potential cellular analyses. At every collection - blood will be centrifuged; plasma and buffy coat aliquoted and stored at - 80 °C. |
- Collect blood (16 mL) between baseline (Screening, Enrollment, and Baseline) - (Visit 1) - Collect Blood (16 mL) end of Radiotherapy (Visit 2) - Collect Blood (16 mL) within 4 months after completion of radiotherapy (Post-Radiotherapy) - (Visit 3)
|
|
Batched analysis of Biomarker dynamic in the saliva including but not limited to cell-free DNA and cytokines, following ConformalFLASH reirradiation for up to 10 participants.
Tidsramme: - Between baseline (Screening, Enrollment, and Baseline Collection) - (Visit 1) - End of Radiotherapy Collection (Visit 2) - Within 4 months after completion of radiotherapy (Post-Radiotherapy Collection) - (Visit 3)
|
Change in biomarker measures (e.g., cell-free DNA and cytokines) in saliva between baseline, end of radiotherapy, and within 4 months after completion of radiotherapy. At each time point, saliva will be collected into a commercial saliva collection tube in accordance with the manufacturer's instructions, after the 30-minute interval. At every collection - Saliva will be stored at - 80 °C. |
- Between baseline (Screening, Enrollment, and Baseline Collection) - (Visit 1) - End of Radiotherapy Collection (Visit 2) - Within 4 months after completion of radiotherapy (Post-Radiotherapy Collection) - (Visit 3)
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Shervin Tabrizi, MD, University of Pennsylvania
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- UPCC 16326
- 26-8473 (Annen identifikator: University of Pennsylvania, Internal Review Broad (IRB))
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .